Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fifteen-year Immunologic Follow-up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the Costa Rica HPV-16/18 Vaccine Trial (CVT): Generating Durability Data: The ESCUDDO-CVT Study

Trial Profile

Fifteen-year Immunologic Follow-up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the Costa Rica HPV-16/18 Vaccine Trial (CVT): Generating Durability Data: The ESCUDDO-CVT Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms The ESCUDDO-CVT Study
  • Most Recent Events

    • 17 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 10 Oct 2018 to 23 Oct 2018.
    • 04 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 27 Sep 2018 to 10 Oct 2018.
    • 21 Sep 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 12 Sep 2018 to 27 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top